Abstract
Classical Hodgkin lymphoma (cHL) is now recognized as a B-cell-derived lymphoma which is characterized by only about 1% malignant pathognomonic Hodgkin and Reed-Sternberg (HRS) cells and an abundant infiltrate of reactive bystander cells. HRS cells are unique with respect to their lost B-cell-specific gene expression pattern and recurrent genetic lesions. Aberrant activity of Notch signaling, a highly conserved developmental pathway, acts as a negative regulator of the B cell program in HRS cells and thereby contributes to their reprogramming. Another striking feature and the major pathogenetic mechanism in HRS cells is constitutive NF-κB activation. A number of aberrations that contribute to canonical NF-κB activity in HRS cells have been described such as genetic lesions, deregulated receptor signaling and Epstein-Barr virus (EBV) infection. The importance of Notch and NF-κB signaling for cHL pathogenesis, their potential cross-talk and implications for future therapeutic applications are being discussed.
Keywords: Notch, NF-κB, Hodgkin lymphoma, B cell lymphoma, Hodgkin/Reed-Sternberg cells, gene transcription, mutations, immunoprecipitation, inflammatory cells, cytokine, helix-loop-helix proteins, Epstein-Barr virus, Multiple Myeloma, B-chronic lymphocytic leukemia, tumor suppressor gene
Current Molecular Medicine
Title: Notch and NF-κB Signaling Pathways in the Biology of Classical Hodgkin Lymphoma
Volume: 11 Issue: 3
Author(s): R. Schwarzer and F. Jundt
Affiliation:
Keywords: Notch, NF-κB, Hodgkin lymphoma, B cell lymphoma, Hodgkin/Reed-Sternberg cells, gene transcription, mutations, immunoprecipitation, inflammatory cells, cytokine, helix-loop-helix proteins, Epstein-Barr virus, Multiple Myeloma, B-chronic lymphocytic leukemia, tumor suppressor gene
Abstract: Classical Hodgkin lymphoma (cHL) is now recognized as a B-cell-derived lymphoma which is characterized by only about 1% malignant pathognomonic Hodgkin and Reed-Sternberg (HRS) cells and an abundant infiltrate of reactive bystander cells. HRS cells are unique with respect to their lost B-cell-specific gene expression pattern and recurrent genetic lesions. Aberrant activity of Notch signaling, a highly conserved developmental pathway, acts as a negative regulator of the B cell program in HRS cells and thereby contributes to their reprogramming. Another striking feature and the major pathogenetic mechanism in HRS cells is constitutive NF-κB activation. A number of aberrations that contribute to canonical NF-κB activity in HRS cells have been described such as genetic lesions, deregulated receptor signaling and Epstein-Barr virus (EBV) infection. The importance of Notch and NF-κB signaling for cHL pathogenesis, their potential cross-talk and implications for future therapeutic applications are being discussed.
Export Options
About this article
Cite this article as:
Schwarzer R. and Jundt F., Notch and NF-κB Signaling Pathways in the Biology of Classical Hodgkin Lymphoma, Current Molecular Medicine 2011; 11 (3) . https://dx.doi.org/10.2174/156652411795243423
DOI https://dx.doi.org/10.2174/156652411795243423 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intraperitoneal Oncolytic and Tumor Vaccination Therapy with Replication-Competent Recombinant Virus: The Herpes Paradigm
Current Gene Therapy Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry Unique Biology of Mcl-1: Therapeutic Opportunities in Cancer
Current Molecular Medicine The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design Applications of Micro/Nanotechnology in Ultrasound-based Drug Delivery and Therapy for Tumor
Current Medicinal Chemistry The Interactions of Anti-Cancer Drugs Approved in the Last Decade in the United States with Membrane Transporters
Anti-Cancer Agents in Medicinal Chemistry Synthesis, DNA Binding Ability and Anticancer Activity of 2-heteroaryl Substituted Benzimidazoles Linked Pyrrolo[2,1-c][1,4]benzodiazepine Conjugates
Medicinal Chemistry Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Promising Anti-Fibrotic Approaches for Future Treatment of Systemic Sclerosis
Current Rheumatology Reviews The Influence of Lipophilicity on the Classification of Antitumor Acridinones Evaluated by Principal Component Analysis
Current Pharmaceutical Analysis A Perspective on Clinical Islet Transplantation: Past, Present and Developments for Future
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Diabetic Retinopathy, Superoxide Damage and Antioxidants
Current Pharmaceutical Biotechnology Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design Yin and Yang of Polyphenols in Cancer Prevention: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction through JAK-STAT and NF-κB Regulated Pim-1 Kinase: Novel Target for Anticancer Leads
Current Signal Transduction Therapy Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response
Current Pharmaceutical Design Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) A Novel Gene Selection Method Based on Sparse Representation and Max-Relevance and Min-Redundancy
Combinatorial Chemistry & High Throughput Screening Exosome-like Nanoparticles: A New Type of Nanocarrier
Current Medicinal Chemistry